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The Shwartzman phenomenon may be defined as the pathologic manifesta- 
tion  of  disseminated  intravascular  coagulation  with  widespread  hemorrhagic 
necrotic lesions and bilateral renal cortical necrosis induced by the administra- 
tion of two spaced injections of endotoxic lipopolysaccharide (LPS).I Results of 
previous investigations indicate  that  the platelet-LPS interaction with  subse- 
quent platelet adherence and release of its contents is primarily responsible for 
the pathologic alterations of the coagulation system (1--6).  Prior treatment of 
rabbits  which  renders  them  thrombocytopenic  or  leukopenic  can  regularly 
protect  these  animals  from  the  manifestation  of  Shwartzman  lesions  (7,  8). 
Stetson found that there was a temporal correlation between thrombocytopenia 
and the deposition of platelet aggregates in the lung, liver, and spleen after the 
administration  of LPS  (1).  Furthermore,  McKay  and  Shapiro  observed that 
LPS-induced  thrombocytopenia  corresponded  well  with  the  appearance  of  a 
hypercoagulable state (2).  Recently,  Mustard  et al. demonstrated the protec- 
tion of rabbits from Shwartzman lesions by treatment with acetylsalicylic acid, 
sulfinpyrazone,  or phenyl  butazone  which  are  agents  that  interfere  with  the 
platelet release reaction (9-11). 
Although the mechanism of platelet-LPS interaction remains to be elucidated, 
Siqueira  and  Nelson  suggested  that  the  complement system is  important  in 
this  interaction  (12).  Review of recent  reports  indicates  that  plasma factors 
are required for the platelet-LPS interaction and that these factors are inhibited 
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by known anticomplementary agents (13). However, direct proof of the comple- 
ment system's participation in the platelet-LPS interaction is lacking. The use 
of anticomplementary agents in vivo prevents Shwartzman lesions (14).  How- 
ever, it has been difficult to interpret these results because anticomplementary 
agents used also cause a  concommitant leukopenia and thrombocytopenia, and 
it is known that the cellular elements are essential for the reaction (12). 
A  cobra  venom  anticomplementary factor  (CVF)  isolated  from  venom  of 
Naja naja or Naja haje appears  to be an ideal anticomplementary agent to be 
used for studying the role of the complement system in the Shwartzman phe- 
nomenon  because  the  CVF  administered  causes  leukocytosis  rather  than 
leukopenia  (15).  Furthermore,  the  duration  of hypocomplementemia induced 
by  CVF is also longer than  that induced by other known anticomplementary 
agents. Results of studies using CVF as the anticomplementary agent, presented 
in  this report,  indicate that  the complement system plays an essential role in 
the pathogenesis of the Shwartzman phenomenon. 
Materials and Methods 
Animals.--Male  and  female albino  rabbits,  weighing between  1.3  to  1.6  kg were used. 
These animals had free access to water and Purina rabbit pellets throughout  the experiments. 
LPS.--Endotoxic  lipopolysaccharide was prepared  from Escherichia coli according to the 
method  of Boivin et al.  (16). This preparation  of LPS was found to have an LDS0 of 500 #g 
when tested against 20 g Swiss Webster white mice. 1.4 #g of this LPS preparation  induced a 
50% inhibition on the total hemolytic activity of 1 ml of 1:5 dilution of normal rabbit serum 
after an incubation  of 60 rain at 37°C. 
Induction of Localized and Generalized Shwartzman Reaction.--For localized Shwartzman 
reaction,  the preparatory  dose was  100 #g  of LPS given intradermally  in the right upper 
quadrant of the abdomen followed by the provoking intravenous  dose of 270 #g of LPS 24 
hr later.  For generalized Shwartzman reaction  two intravenous  doses of 270 #g of LPS were 
given 24 hr apart.  To study  both the generalized and localized Shwartzman  reaction in the 
same rabbit,  both the intradermal  and intra~venous dose of LPS were given simultaneously 
followed by the provocative dose in 24 hr. With such a scheme, we were able to induce regu- 
larly both localized and generalized Shwartzman lesions in more than 80% of the rabbits. 
CVF.--Lyophilized  cobra venom (Naja haje) was purchased  from Ross Allen Reptile In- 
stitute, Inc.,  Silver Springs, Fla.  The anticomplementary  CVF was isolated from the cobra 
venom  by  diethylaminoethyl  (DEAE)-cellulose  column  chromatography  as  described  by 
Ballow and Cochrane  (17). No attempt was made to further  purify the CVF by Sephadex or 
sodium  carboxymethylceUulose  (CM)-cellulose  chromatography.  The  anticomplementary 
activity of the CVF was assayed  according to the method  of Cochrane  et al.  We modified 
their method  by using 5 X  107 sensitized sheep cells, adjusting  the final volume to 7.5 ml 
and measuring the amount  of hemolysis at 412 nm (15). Our CVF preparation  was found to 
have 80 units of anticomplementary  activity/ml  when one unit of anticomplementary  activity 
is defined as the reciprocal of the dilution of the CVF preparation  in 0.1 ml volumes which 
reduces the hemolytic activities of 0.4 ml of a 1:20 dilution of normal human serum by 50%, 
after an incubation  period of 20 min at 37°C. 
Experimental Design.--Rabbits  were  divided  randomly  into  experimental  and  control 
groups. A total of 30 rabbits were studied in five separate experiments; assays on blood sam- 
ples were carried  out for  10 animals in each group. The experimental  group received three 644  PREVENTION  OF  THE  SHWARTZMAN REACTION 
intravenous injections of CVF (total dose of 320 anticomplementary units/kg of rabbit)  at 
--24,  --20, and  --16 hr; the control group received saline (sodium chloride injection, USP, 
Cutter Laboratories, Berkeley, Calif.)  of identical volumes and at similar time intervals. 
At zero time each rabbit was injected with 100  ~g of LPS intradermally and 270/~g  of 
LPS intravenously; this was followed by a provocative dose of 270 ~g of LPS intravenously 
24 hr later. Blood samples from each animal were collected from the ear artery immediately 
before the first dose of CVF or saline; immediately before the preparatory dose of LPS; and 
at 28, 48, 72, and 96 hr after the initial LPS injections. On each of these blood samples the 
following assays were performed: white cell count, platelet count, fibrinogen and fibrin degra- 
dation products, fibrinogen level, and hemolytic complement activity. 
Cell Counts.--White blood cell counts were performed manually by standard techniques. 
Platelet counts were performed with the use of 1% ammonium oxalate solution as the diluting 
fluid and a phase-contrast microscope as was described by Brecher et al. (18). 
Fibrinogen and Fibrin Degradation Products.--The staphylococcal clumping test of Hawiger 
et al. for the determination of fibrinogen and fibrin degradation products was performed with 
modifications (19). 0.96 ml of blood was collected into a test tube containing 0.04 ml of epsilon- 
aminocaproic acid  (EACA)  and  thrombin  (EACA  5  mg and  thrombin  2  units/0.04  ml). 
EACA was obtained from Lederle Laboratories, Pearl  River, N.  Y.;  thrombin from The 
Upjohn Company, Kalamazoo, Mich. After collection,  the blood  sample was incubated at 
37°C for 1 hr and the serum separated by centrifugation and stored at --20°C until use. The 
clumping positive Staphylococcus aureus (strain Newman D~C)  was kindly provided by Dr. J. 
Hawiger (Vanderbilt University School of Medicine, Nashville, Tenn.). To assay the fibrino- 
hen and fibrin degradation products titer, the staphylococcal clumping test was carried out 
with the use of 0.025 ml microdiluters and microtiter plates (Cooke  Engineering Co., Alex- 
andria, Va). Lyophilized preparations of the bacteria were prepared as described (19) and 
suspended at a  concentration of 2.5  mg/ml in 0.05  M tris  (hydroxymethyl) aminomethane 
(Tris) buffer containing 0.01% bovine serum albumin at pH 7.4. With the use of microdiluters, 
serum samples were serially diluted in 0.025 ml volumes of the same buffer. An equal volume 
of the bacteria suspension was then added. The microtiter plate was gently agitated for 2 
min and its contents allowed to settle at room temperature for 30 rain before the clumping 
titer was scored. 
Fibrinogen  Determination.--A  modified method of Ratnoff and Menzie for fibrinogen de- 
termination was used (20). Briefly, 0.95 ml of blood was collected into a test tube containing 
0.05  ml of 0.1 ~  EDTA  (ethylenediaminetetraacetate sodium), pH 7.4. 50  ~1  of  the  fresh 
plasma were transferred to another test tube containing 2  ml of normal saline at pH 7.4, 100 
#1  of thrombin (1000 units/10 ml, Upjohn), and approximately 0.5  volume  of glass beads 
(Super-brite glass beads, 200 ~ in diameter, Minnesota Mining and Manufacturing Co., St. 
Paul, Minn.). The tube contents were mixed and allowed to sit at room temperature for 20 
rain. A Vortex-Genie mixer (Scientific Industries Inc., Springfield,  Mass.) was used to ensure 
thorough mixing so that all  clottable proteins were trapped onto glass beads. The soluble 
proteins in the supernatant were removed by three successive washings with normal saline. 
After the addition of 1 ml of 10% sodium hydroxide solution, the tube was boiled in a water 
bath for 10 min and allowed  to cool. The following reagents were added in sequence with mix- 
ing: 7 ml of  distilled water, 3  ml of  20% sodium carbonate solution, and 1 ml of  phenol 
reagent (Harleco,  Philadelphia, Pa.). After a 10  min room temperature incubation, a spectro- 
photometric determination of the tube content at 650 nm was performed with a  Coleman 
Junior Spectrophotometer. A standard curve was obtained by the determination of standard 
tyrosine solution in 0.1 N hydrochloric acid. It is possible to match the optical density values 
of fibrinogen determination with that of the standard  curve so that  corresponding amounts 
of tyrosine may be obtained. The amount of fibrinogen was calculated by multiplying the 
amount of corresponding tyrosine by a  conversion factor of 11.7. JACK S.  C.  FONG AND  ROBERT A.  GOOD  645 
Hemolytic Complement Determination.~The preparation of buffers and sheep erythrocytes 
sensitized with rabbit hemolysin have been described previously (21). Rabbit serums were 
serially diluted in 0.5 ml volumes of glucose-gelatin-barbitM-buffered saline containing cal- 
cium and magnesium at pH 7.4. Mter the addition of 0.5 ml of sensitized sheep erythrocytes 
at 1 ;< 10 s ml  -I, the mixtures were incubated  at 37°C for 60 rain. The amount of hemolysis 
was determined at 412 nm and the CHs0 value calculated. 
RE6ULTS 
Pathogenic  Examination.--Both  the  experimental  and  control  groups  of 
animals were  examined for  kidney,  skin,  liver,  and lung lesions 96  hr  after 
TABLE  I 
Pathologic Assessment  of CVF or Saline-Treated  Rabbits Subjected  to the Induction  of 
Shwartzman Reactions by Endotoxin  Injections 
Treatment  CVF  Saline 
Site examined  Kidney  Localized  Liver  Lung  Kidney Localized  Liver  Lung  skin  skin 
Hemorrhagic  1/15  1/15  0/15  6/15  12/15  12/15  9/15  13/15 
necrosis* 
Severity  of  +J~  10 mm§  0J~  +:~  3+  17 mm  1+  2+ 
pathology 
* Expressed as the No. of positive responses over the No. of rabbits studied. 
:~ Severity of pathology expressed on a scale of 0 to 4+ ; where 
0 =  no gross lesion 
+  =  fine petechial hemorrhage 
2+  =prominant but discrete "flea-bite" hemorrhage 
3+  =  coalescent hemorrhagic areas 
4-t- =  massive hemorrhagic lesion. 
§ Average diameter of the hemorrhagic necrotic area. 
initial LPS injection when they were sacrificed or at an earlier time if they died 
spontaneously. Observations in the gross were checked by histologic examina- 
tion for fibrin deposition. The characteristic blue color on phosphotungstic acid 
hematoxylin staining was considered diagnostic of fibrin deposition. Results of 
these experiments are presented in Table I. It is apparent that animals treated 
with CVF are protected from both the localized and generalized Shwartzman 
reactions.  Of  the  CVF-treated  group  only one  of  15  rabbits  developed  the 
localized and generalized Shwartzman reactions and they were mild. However, 
fine petechial hemorrhages of lungs were noted in approximately 40%  of  the 
CVF-treated animals. The control group responded to the LPS challenge more 
frequently  and  also  more  vigorously. Histologic  examinations  of  the  skin 
biopsies taken 20 hr after  the preparatory intradermal dose  of LPS  revealed 646  PREVENTION  OF  THE  SHWARTZMAN REACTION 
identical  characteristics  for  both  groups  of  animals.  However,  the  control 
animals  were  susceptible  to  the  challenging  dose  of  LPS  and  manifestated 
hemorrhagic necorsis at the prepared skin site. By contrast,  the  CVF-treated 
animals were resistant to these pathologic changes. 
White Blood Cell Count.--In view of the protective role of leukopenia against 
the  development of localized  and  generalized  Shwartzman  reaction,  it  is im- 
portant  to  determine  the  white  cell  count  after  the  administration  of  CVF. 
Furthermore, the changes in the circulating white blood cells during the course 
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Fro. 1. White blood cell counts of rabbits pretreated with CVF (----)  or saline (--) 
and followed by endotoxin injections for inductions of localized and generalized Shwartzman 
reactions. Pretreatment  injections were given at  --24,  -20, and  --16 hr; LPS injections 
given at 0 and 24 hr. 
of lesion development were studied. The mean values of 10 blood samples from 
each of the experimental and control groups are presented in Fig. 1. As reported 
earlier,  the  administration  of  CVF  induced  a  leukocytosis  response  so  that 
circulating  white  blood  cell  count  was  approximately  doubled  within  24  hr. 
After the injection of LPS, both experimental and control animals responded 
similarly within the first 28 hr. However, the leukopenia was less for the CVF- 
treated  group  than  that  for  the  control.  By  the  48th  hr  the  control  group 
reached a peak level of leukocytosis while the CVF-treated animals responded 
only slightly. Such a leukocytosis response by control animals probably repre- 
sents an acute phase or response to inflammatory reaction directed against the JACK  S.  C.  FONG  AND  ROBERT  A.  GOOD  647 
disseminated  intravascular  coagulation.  Protection  conferred  by  CVF  from 
Shwartzman reaction is certainly not due to a leukopenia. 
Platelet Count.--The platelet count is a valuable assay for the assessment of 
Shwartzman reaction since changes in circulating platelet levels correspond to 
presumed pathogenetic events in Shwartzman reaction. Furthermore, platelet- 
LPS  interaction  is  believed  to  be  primarily  responsible  for  the  initiation  of 
Shwartzman lesions  (1-6).  The mean values of  10 platelet counts are plotted 
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FIG.  2.  Platelet counts  of rabbits pretreated  with CVF  (- -  -  -)  or saline  (--)  and fol- 
lowed by endotoxin  injections  for inductions  of localized  and generalized  Shwartzman reac- 
tions.  Pretreatment  injections  were given  at  --24,  --20,  and  --16  hr; LPS injections  given 
at 0  and 24 hr. 
against time in Fig.  2.  No significant changes occurred in circulating platelet 
levels  after  CVF  administration. When LPS  was given intravenously, unpro- 
tected animals showed precipitous drops in their circulating platelet levels and 
little evidence of recovery from the thrombocytopenic state even as late as the 
96th  hr  after  the  first  LPS  injection.  By  contrast  to  controls,  CVF-treated 
animals  showed  only a  mild  decrease  in circulating platelet  levels  after LPS 
administration, and they were able to respond rapidly with thrombocytosis. 
Fibrinogen  and  Fibrin Degradation  Products.--The  detection  of  fibrinogen 
and fibrin degradation products in circulation reflects the occurrence of fibrino- 648  PREVENTION  OF  THE  SHWARTZMAN  REACTION 
lysis.  Results  of these  studies  using  the  staphylococcal clumping test are pre- 
sented as mean values of 10 determinations  and expressed as log2 of reciprocal 
dilutions in Fig. 3. No significant amounts of fibrinogen and fibrin degradation 
products  were  detected  in  CVF-treated  animals  throughout  the  experiment. 
However,  in  the  control  animals,  fibrinogen  and  fibrin  degradation  product 
titers  became markedly elevated  by the  24th  hr and  continued  to rise  to the 
peak level by the 48th  hr.  Over the last  2  days of the  experiment,  a  gradual 
decline  of  this  titer  was  observed.  Thus  in  the  phase  of disseminated  intra- 
vascular  coagulation,  control  rabbits  were  able  to  respond  with  fibrinolysis 
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FIG. 3.  Fibrinogen and fibrin degradation  titers of rabbits  pretreated  with CVF (  ....  ) 
or saline  (  ) and followed by endotoxin injections for inductions  of localized and gen- 
eralized Shwartzman reactions. Pretreatment  injections were given at --24, --20, and  -16 
hr; LPS injections given at 0 and 24 hr. 
but this response was insufficient to prevent tissue damage as a consequence of 
the intravascular coagulation. 
Fibrinogen.--Fibrinogen plays an important role as the final  common path- 
way for Shwartzman reaction or any disseminated  intravascular  coagulopathy 
in  that  fibrin  deposition  is  responsible  for  tissue  damage  whereas  fibrinogen 
deprivation or fibrin removal provides protection. The mean fibrinogen values 
of  10 samples  are plotted  against  time  in  Fig.  4.  After  the  administration  of 
CVF  an  increase  of fibrinogen  level  occurred.  The  preparatory  dose  of LPS 
induced  a  similar  decrease  of circulating  fibrinogen  levels  in  both  groups  of 
animals. However, control animals responded with hyperfibrinogenemia within 
24 hr while CVF-treated animals had only a  slight increase of fibrinogen level. lACK S.  C.  FONG AND ROBERT A.  GOOD  649 
in control animals the provocative dose of LPS produced a precipitous drop of 
fibrinogen  level  which  was  again  followed  by  rapid  development  of  hyper- 
fibrinogenemia. By contrast, CVF-treated animals showed only a small drop of 
fibrinogen level after the  second dose of LPS,  and  no  reactive hyperfibrino- 
genemia was observed. 
Hemolytic Complement Assay.--The mean CHs0 values of 10 samples of each 
group of animals were plotted  against time in  Fig.  5.  Injections of 320  CVF 
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FIG. 4. Fibrinogen levels of rabbits pretreated with CVF (- - - -) or saline (--)  and 
followed by endotoxin injections for inductions of localized and  generalized Shwartzrnan 
reactions. Pretreatment  injections were given at  --24,  --20, and  --16 hr;  LPS injections 
given at 0 and 24 hr. 
anticomplementary units/kg  of  rabbit  given  in  three  divided  doses  by  four 
hourly intervals failed to produce signs of hemoglobinuria or hemoglobinemia. 
24 hr after the initial dose of CVF, the total hemolytic complement activity was 
regularly less than 10% of pretreatment values. The preparatory dose of LPS 
induced a mild increase of hemolytic complement activity in both experimental 
and  control  animals.  After  the provocative dose of LPS,  a  rapid  decrease of 
hemolytic complement activity in the control group occurred which contrasted 
with an increase of hemolytic complement activity in the CVF-treated group. 
Little variation in the CHs0 values in both groups of animals occurred during 
the last 3 days of the experiment. 650  PREVENTION  OF  THE  SHWARTZMAN  REACTION 
DISCUSSION 
Antigen-antibody complexes may be used to replace LPS in the induction of 
pathologic responses in  animal models (22).  The resemblance of many of the 
biological activities mediated by LPS  to those produced by antigen-antibody 
complexes led investigators to study the complement system which might act 
as the common pathway for amplification of biologic responses (13, 23). It has 
been Well established  that LPS reacts with  serum cofactor(s)  in  the presence 
of  magnesium  to  form  a  molecular  complex  which  consumes  the  classical 
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Fro. 5. Total hemolytic complement activities of rabbits pretreated with CVF (- - - -) or 
saline (--)  and followed  by endotoxin injections for inductions of localized and generalized 
Shwartzman reactions. Pretreatment  injections were given at --24,  --20, and  -16 hr; LPS 
injections given at 0 and 24 hr. 
terminal complement components (C3-C9). During this interaction biologically 
active fragments are  generated  and  released  (13,  24).  This  report  represents 
an attempt to modify LPS-mediated Shwartzman reactions by prior consump- 
tion  of  terminal  complement  components  with  a  cobra  venom  anticomple- 
mentary  factor.  Our  results  show  that  CVF-treated  animals  are  protected 
from the manifestations of disseminated intravascular coagulation and bilateral 
renal cortical necrosis. Since the CVF-induced hypocomplementemia is a  rela- 
tive but not an absolute deficiency, it is not surprising to find that 40 % of the 
treated  animals had petechial hemorrhages in  their lungs.  Untreated  animals 
showed lesions that were qualitatively and quantitatively different from those 
of the CVF-treated group. JACK  S.  C.  FONG  AND  ROBERT  A.  GOOD  651 
Prior  studies  have  revealed  that  both platelets  and  white  blood cells  are 
essential to the expression of both localized and generalized Shwartzman reac- 
tions (7i 8). The use of CVF as the anticomplementary agent had the advantage 
of  permitting  study  of  animals  responding with  leukocytosis.  Furthermore, 
neutrophils isolated from CVF-treated rabbits showed no deficit in their capac- 
ity to respond to a chemotactic stimulus (15). The depletion of terminal comple- 
ment components, mainly C3,  by CVF  appears to influence the white blood 
cell responses towards LPS administration only moderately. Thus no histologic 
differences of skin biopsies were noted in control or CVF-treated rabbits 20 hr 
after the  intradermal  injection of LPS.  This  observation suggests  that LPS 
might utilize noncomplement-dependent chemotactic mechanisms or be respon- 
sible for generating an adequate quantity of chemotactic factors (e.g. C5a or 
C567)  using the small amount of C3 available. 
When the sequence of events involved in the pathogenesis of Shwartzman 
reaction in control and CVF-treated animals were considered, there could be 
no question that hypocomplementemia was  associated with a  protective role 
towards circulating platelets. In CVF-treated rabbits, no substantial alterations 
in circulating fibrinogen levels were observed, a finding that corresponded well 
with the minor changes in platelet levels seen in these rabbits.  Furthermore, 
the  CVF  protection did  not  appear  to  act via  the  induction  of fibrinolytic 
activities, because no significant amount  of circulating fibrinogen and fibrin 
degradation products was detected. In control animals, the drop of circulating 
platelet counts correlated well with changes of fibrinogen levels. Furthermore, 
in control rabbits after the first injection of LPS, we demonstrated the appear- 
ance of fibrinogen and fibrin degradation products. The level of fibrinogen and 
fibrin degradation products was increased by the provocative dose of LPS and 
persisted in circulation for at least 3 days. Since McKay and Shapiro could not 
demonstrate  any  circulating  fibrinogenolytic activity in  rabbits  manifesting 
Shwartzman  reaction  (2),  these  results  indicated  that  rabbits  were  able  to 
respond  with  local  fibrinolytic  activities  to  the  disseminated  intravascular 
coagulation by releasing fibrinogen and fibrin degradation products but without 
demonstrating significant amounts of circulating plasmin activity. 
In normal rabbits after the preparatory dose of LPS, a mild increase of the 
hemolytic complement activity, probably as a consequence of an inflammatory 
response, occurred. Upon the injection of the provocative dose of LPS, a  de- 
crease in  the hemolytic complement activity occurred which  correlated with 
analogous  changes  in  white  blood  cell,  platelet,  and  fibrinogen  levels.  The 
hemolytic complement activity then remained at  this lower level from 28th 
to 96th hr of the experiment. For CVF-treated rabbits, LPS appeared to stimu- 
late resulting increased hemolytic complementary activity. At the time of the 
provocative LPS dose,  hemolytic complement activities were  about  25 %  of 
those observed before CVF treatment. 652  PREVENTION  OF  THE  SHWARTZMAN  REACTION 
It seems likely to us that prevention of Shwartzman reaction by CVF-induced 
hypocomplementemia reflects an  essential role of the  complement system in 
mediating platelet-LPS interaction. Whether the mode of complement partici- 
pation is like that involved for particulate antigen and antibody interactions 
as described by Henson and Cochrane (25)  remains conjectural. The concept 
that LPS activates the complement system through very avid antibodies and 
by an extremely efficient use of early acting complement components would 
favor this view of complement-mediated platelet-LPS  interactions (13,  26). 
However, prior immunization of animals to LPS protects against rather than 
to enhance Shwartzman lesions. That complement-independent immune plate- 
let aggregation (27) is operative in Shwartzman reaction seems unlikely because 
CVF-induced hypocomplementemia is associated with such striking protection. 
Dodds and Pickering demonstrated alterations of hemostasis in guinea pigs 
after a single intraperitoneal injection of CVF (28). Possible mechanisms enter- 
tained by these investigators were a  direct effect of CVF on platelets and an 
indirect induction of intravascular hemolysis. However the period of alterations 
of hemostasis in  these guinea pigs was less  than 21  hr.  We could detect no 
evidence of intravascular hemolysis in our animals after the administration of 
CVF. Furthermore, the provocative dose of LPS was given 40 hr after the last 
dose of CVF so that any occurrence of hemostatic alterations would not have 
persisted to that time. Thus the prevention of Shwartzman reaction by CVF 
almost certainly operated by the hypocomplementemia which protects circu- 
lating platelets from reacting with LPS. Recently the interaction of coagulation 
and immune systems has been emphasized (29, 30). Indeed, the substitution of 
LPS by antigen-antibody complexes in the induction of Shwartzman reactions 
was well established (31, 32). Understanding of immune-mediated coagulopathy 
may help us gain further insight in the nature of immunologic injury and may 
offer new approaches for immunologic manipulation. 
SUMMARY 
Both localized and generalized Shwartzman reactions were induced in  the 
same rabbits by simultaneous administration of preparatory intravenous and 
intradermal  doses  of  endotoxin followed in  24  hr  by  the provocative  dose. 
Control rabbits with more than 80% positive responses showed corresponding 
changes of platelet,  white blood cell,  fibrinogen, and hemolytic complement 
levels.  Circulating fibrinogen and  fibrin  degradation products  were detected 
shortly after the preparatory dose and persisted for at least 3 days. Rabbits 
given  cobra  venom  anticomplementary factor showed hypocomplementemia 
(less than 10% of normal), leukocytosis, and elevated fibrinogen levels. After 
the administration of endotoxin, only one of 15 CVF-treated animals developed 
a  Shwartzman reaction and that was mild. These rabbits showed only minor 
changes of platelet and fibrinogen levels throughout the experiment although JACK S.  C.  FONG AND ROBERT A.  GOOD  653 
their white blood cell responses were siinilar  to those of the control group. No 
detectable fibrinogen and fibrin degradation products appeared in circulation, 
and  the  hemolytic complement  activity  increased  gradually beginning  with 
the  preparatory  dose  of  endotoxin.  Thus  depletion  of  terminal  complement 
components (mainly C3)  in  rabbits  is  protective against  the development of 
both localized and generalized Shwartzman reactions; its mechanism of action 
is  probably through  the  sparing  of platelets  by inhibiting  platelet-endotoxin 
interaction. The essential role of the complement system in Shwartzman reac- 
tion indicates  that  this  coagulopathy probably represents  a  manifestation  of 
immunologic injury. 
The authors are grateful to acknowledge the invaluable technical assistance of Misses 
Susan Barrett, Jean Lindorfer, and Nancy Richardson and the excellent preparation of the 
manuscript by Mrs. Toni Burns. 
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